SELLAS Life Sciences (SLS) Operating Leases (2019 - 2026)
SELLAS Life Sciences (SLS) reported Operating Leases of $871000.0 for Q1 2026, up 181.88% year-over-year from $309000.0 in Q1 2025, and up 90.59% on a QoQ basis from $457000.0 in Q4 2025.
SELLAS Life Sciences (SLS) has 8 years of Operating Leases data on file, last reported at $871000.0 in Q1 2026.
- Quarterly Operating Leases rose 181.88% year-over-year to $871000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $871000.0 (up 181.88% YoY) and the FY2025 annual result came in at $457000.0, changed 0.0% from the prior year.
- Operating Leases climbed to $871000.0 in Q1 2026 per SLS's latest filing, from $457000.0 in the prior quarter.
- Across five years, Operating Leases topped out at $1.2 million in Q1 2022 and bottomed at $157000.0 in Q2 2025.
- The 5-year median for Operating Leases is $460000.0 (2023), against an average of $600400.0.
- The widest annual swing landed in 2023, when Operating Leases sank 82.82%; it then surged 181.88% in 2026.
- Tracing SLS's Operating Leases over 5 years: stood at $573000.0 in 2022, then decreased by 19.72% to $460000.0 in 2023, then slipped by 0.65% to $457000.0 in 2024, then changed by 0.0% to $457000.0 in 2025, then soared by 90.59% to $871000.0 in 2026.
- Per Business Quant, the three latest SLS Operating Leases figures stand at $871000.0 (Q1 2026), $457000.0 (Q4 2025), and $157000.0 (Q2 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn |
| 10 | SELLAS Life Sciences | 1.61 Bn | 1.61 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 871,000.00 |
| Dec 31, 2025 | 457,000.00 |
| Jun 30, 2025 | 157,000.00 |
| Mar 31, 2025 | 309,000.00 |
| Dec 31, 2024 | 457,000.00 |
| Jun 30, 2024 | 692,000.00 |
| Mar 31, 2024 | 313,000.00 |
| Dec 31, 2023 | 460,000.00 |
| Sep 30, 2023 | 178,000.00 |
| Jun 30, 2023 | 749,000.00 |
| Mar 31, 2023 | 422,000.00 |
| Dec 31, 2022 | 573,000.00 |
| Sep 30, 2022 | 1.04 Mn |
| Jun 30, 2022 | 1.12 Mn |
| Mar 31, 2022 | 1.21 Mn |
| Dec 31, 2021 | 610,000.00 |
| Sep 30, 2021 | 667,000.00 |
| Jun 30, 2021 | 903,000.00 |
| Mar 31, 2021 | 775,000.00 |
| Dec 31, 2020 | 825,000.00 |
| Sep 30, 2020 | 873,000.00 |
| Jun 30, 2020 | 900,000.00 |
| Mar 31, 2020 | 123,000.00 |
| Sep 30, 2019 | 306,000.00 |
| Jun 30, 2019 | 28,000.00 |
| Mar 31, 2019 | 471,000.00 |